Canada - English - Health Canada

boehringer ingelheim animal health canada inc. - hyaluronate sodium - solution - 10mg - hyaluronate sodium 10mg - horses

Australia - English - Department of Health (Therapeutic Goods Administration)

australian naturalcare products pty ltd - glucosamine sulfate potassium chloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

australian naturalcare products pty ltd - glucosamine sulfate potassium chloride,natural fish oil -

Australia - English - Department of Health (Therapeutic Goods Administration)

australian naturalcare products pty ltd - glucosamine sulfate potassium chloride, quantity: 1.992 g (equivalent: potassium chloride, qty 490.45 mg; equivalent: glucosamine sulfate, qty 1.5 g) - tablet, film coated - excipient ingredients: microcrystalline cellulose; macrogol 400; povidone; hypromellose; colloidal anhydrous silica; croscarmellose sodium; purified talc; macrogol 8000; magnesium stearate; carnauba wax; titanium dioxide - helps decrease/reduce/relieve cartilage loss/wear/tear/damage ; anti-inflammatory/relieve inflammation ; decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis (linked indication:decrease/reduce/relieve mild joint aches and pains; decrease/reduce/relieve mild joint inflammation/swelling; maintain/support joint mobility/flexibility; decrease/reduce/relieve mild joint pain/soreness; decrease/reduce/relieve mild joint stiffness); helps maintain/supports healthy joint cartilage growth/development/production ; helps maintain/support joint cartilage health ; helps enhance/promote healthy joint function ; helps enhance/promote joint health ; maintain/support joint health

Canada - English - Health Canada

glaxosmithkline inc - tretinoin - cream - 0.025% - tretinoin 0.025% - cell stimulants and proliferants

Canada - English - Health Canada

dechra ltd - hyaluronate sodium - solution - 17mg - hyaluronate sodium 17mg - horses

Canada - English - Health Canada

biomarin international limited - elosulfase alfa - solution - 1mg - elosulfase alfa 1mg - enzymes

United States - English - NLM (National Library of Medicine)

biomarin pharmaceutical inc. - elosulfase alfa (unii: odj69jzg85) (elosulfase alfa - unii:odj69jzg85) - elosulfase alfa 5 mg in 5 ml - vimizim (elosulfase alfa) is indicated for patients with mucopolysaccharidosis type iva (mps iva; morquio a syndrome). none pregnancy exposure registry there is a morquio a registry that collects data on pregnant women with mps iva who are treated with vimizim.  contact mars@bmrn.com or call 1-800-983-4587 for information and enrollment. risk summary available data from published case reports and postmarketing experience with vimizim use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reproduction studies, no effects on embryo-fetal development were observed in rats given daily administration of elosulfase alfa up to 33 times the human steady-state auc (area under the concentration-time curve) at the recommended human weekly dose premating and through the period of organogenesis. no effects on embryo-fetal development were observed in rabbits given daily administration of elosulfase alfa at doses up